Eli Lilly and WHO Foundation Collaborate on Obesity
Analysis based on 8 articles · First reported Mar 06, 2026 · Last updated Mar 06, 2026
The collaboration between Eli Lilly and Company and the WHO Foundation is expected to have a positive impact on the healthcare market, particularly in the obesity care sector, by strengthening health systems and promoting early diagnosis and care. This initiative could also enhance the public image and market sentiment for both Eli Lilly and Company and the WHO Foundation.
The WHO Foundation announced a collaboration with Eli Lilly and Company to strengthen health systems for obesity prevention and care globally. Eli Lilly and Company is committing $1.68 million to the WHO Foundation until 2029 to support these efforts. The initiative aims to address obesity as a public health priority, enable access to early diagnosis, counseling, and care, and reduce the worldwide economic impact of obesity. Anil Soni, CEO of the WHO Foundation, and Patrik Jonsson, Executive Vice President and President of Lilly International, highlighted the importance of this collaboration in building robust health systems and slowing the global progression of obesity.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard